Premium
Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia
Author(s) -
BritoBabapulle F.,
Catovsky D.,
Galton D. A. G.
Publication year - 1987
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1987.tb01325.x
Subject(s) - medicine , myelodysplastic syndromes , bone marrow , myeloid , myeloid leukaemia , haematopoiesis , gastroenterology , pathology , stem cell , biology , genetics
Summary Primary myelodysplastic syndromes progress to acute myeloid leukaemia (AML) in about 30% of cases. We have sought evidence of pre‐existing trilineage myelodysplasia (TMDS) using the FAB criteria (1982) in 160 consecutive cases of primary de novo AML. TMDS was found in 24 cases (15%) including two of 33 cases of Ml (6%), four of 40 cases of M2 (10%), none of 18 cases of M3, five of 31 cases of M4 (15%), six of 30 cases of M5 (20%), all of six cases of M6 and one of two cases of M7. The median presentation bone‐marrow blast‐cell count in the 24 AML/TMDS cases was 53% (30–90%) and 82% (45–100%) in the 136 cases of AML without TMDS. 60% of the AML/TMDS bone‐marrow aspirates contained fewer than 60% of blasts compared with only 11% of those from AML without TMDS ( P <0.001). In AML the occurrence of symptomatic cytopenias when the marrow blast‐cell count is below 60% and the peripheral blood blast‐cell count is below 20% is highly correlated with dysplastic haemopoiesis ( P <0.001).